iBio - Die Impfstoffmaschine (Seite 1824)
eröffnet am 16.03.11 21:21:25 von
neuester Beitrag 02.05.24 21:50:27 von
neuester Beitrag 02.05.24 21:50:27 von
Beiträge: 18.250
ID: 1.164.726
ID: 1.164.726
Aufrufe heute: 0
Gesamt: 2.207.239
Gesamt: 2.207.239
Aktive User: 0
ISIN: US4510337086 · WKN: A3E2GR · Symbol: IBIO
1,8500
USD
-1,60 %
-0,0300 USD
Letzter Kurs 11.05.24 NYSE Arca
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
hier wird Geschichte geschrieben $$$-€€€
Pipeline
.
.
das Volumen ist 10 mal so hoch wie am gestriegen Handelstag
.
https://www.deutsche-bank.de/pfb/content/marktinformationen/…
.
https://www.deutsche-bank.de/pfb/content/marktinformationen/…
Trading Spotlight
IBIO bald bei der magischen Dollar-Grenze.
Zahlenwerk wird helfen. IBIO explodiert weiter.
Zahlenwerk wird helfen. IBIO explodiert weiter.
ich habe die Aktie nicht.
iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology - Apr 24, 2014
http://finance.yahoo.com/news/ibio-receives-patent-allowance…
"NEWARK, DE--(Marketwired - Apr 24, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines.
"The invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins," said Dr. Wayne Fitzmaurice, iBio's vice-president of intellectual property. "The allowed claims cover both composition of matter and uses of the technology for both therapeutic products and vaccines."
Robert Erwin, iBio's president, commented: "China is another important market for our technology and products. Like Brazil, China is a fast growing healthcare market which has no substantial history or prior commitment to older biotechnologies that would compete with our iBioLaunch™ and iBioModulator™ solutions."
The company recently launched a new subsidiary, iBio Brazil, to facilitate entry of biosimilar therapeutics in Brazil. iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 in Brazil to develop a recombinant yellow fever vaccine based upon iBio technology. iBio's success in Brazil is expected to serve as a template for other iBio projects worldwide.
The allowed patent application, "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides," is based on an invention developed by scientists at the company's research and technology collaborator, the Fraunhofer USA Center for Molecular Biotechnology. The invention is owned by iBio. When this patent issues, it will add to the company's fusion protein and iBioModulator patents in the U.S., Australia, Canada, India and Europe (Germany, France, Italy, Ireland, Spain, and Great Britain).
About iBio, Inc.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com. "
iBio Receives Patent Allowance in China for Fusion Protein Compositions and Technology - Apr 24, 2014
http://finance.yahoo.com/news/ibio-receives-patent-allowance…
"NEWARK, DE--(Marketwired - Apr 24, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines.
"The invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins," said Dr. Wayne Fitzmaurice, iBio's vice-president of intellectual property. "The allowed claims cover both composition of matter and uses of the technology for both therapeutic products and vaccines."
Robert Erwin, iBio's president, commented: "China is another important market for our technology and products. Like Brazil, China is a fast growing healthcare market which has no substantial history or prior commitment to older biotechnologies that would compete with our iBioLaunch™ and iBioModulator™ solutions."
The company recently launched a new subsidiary, iBio Brazil, to facilitate entry of biosimilar therapeutics in Brazil. iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 in Brazil to develop a recombinant yellow fever vaccine based upon iBio technology. iBio's success in Brazil is expected to serve as a template for other iBio projects worldwide.
The allowed patent application, "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides," is based on an invention developed by scientists at the company's research and technology collaborator, the Fraunhofer USA Center for Molecular Biotechnology. The invention is owned by iBio. When this patent issues, it will add to the company's fusion protein and iBioModulator patents in the U.S., Australia, Canada, India and Europe (Germany, France, Italy, Ireland, Spain, and Great Britain).
About iBio, Inc.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com. "
schöner Upmove.
Kommt gut. Bloss aufpassen wegen der 1-$ Grenze
Kommt gut. Bloss aufpassen wegen der 1-$ Grenze
iBio Pharmaceutical Technology Embraced by the Government of Brazil
The ministry will invest U.S. $ 170 million in the construction of the first national factory of organic products made from plant cell technology unprecedented in the country, in Ceara.
The ministry will invest U.S. $ 170 million in the construction of the first national factory of organic products made from plant cell technology unprecedented in the country, in Ceara.
Durchsuchen
